News | May 07, 2026
CARBOGEN AMCIS Shanghai site clears unannounced NMPA GMP inspection
Successful inspection outcome strengthens company’s regulatory compliance and manufacturing standards in China
Successful inspection outcome strengthens company’s regulatory compliance and manufacturing standards in China
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
The company’s largest center for medical device applications, serving the entire Asian market
The pharmaceuticals laboratory supports North Asia with formulation development, reverse engineering, troubleshooting, and analysis for various dosage forms
A five-day inspection was concluded successfully with no critical and no major observations raised
Argo will receive upfront payments of US$ 185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.
The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges
Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA in China
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
Subscribe To Our Newsletter & Stay Updated
